Elicio Therapeutics (ELTX) investor relations material

Company overview and technology

• Focuses on lymph node-targeted cancer immunotherapies using the Amphiphile (AMP) platform, developed at MIT, to enhance immune response against cancer.

• Lead candidate ELI-002 targets seven common KRAS mutations and has shown promising results in phase I and II trials.

• Proof of concept established in completed early-phase trials, with ongoing development in both minimal residual and metastatic disease settings.

Industry landscape and differentiation

• Recent cancer vaccine advances highlight the importance of tumor type and immunotherapy sensitivity, with melanoma showing better outcomes than colorectal cancer.

• ELI-002 targets essential, non-escapable driver mutations, unlike many personalized vaccines that risk escape mutations.

• Off-the-shelf approach aims to overcome manufacturing and cost challenges seen in personalized therapies.

Clinical data and development strategy

• Three patients who progressed on ELI-002 in the AMPLIFY-7P trial and then received checkpoint plus chemo achieved complete radiographic and metabolic responses, an uncommon outcome in metastatic pancreatic cancer.

• Translational data show persistent KRAS-specific T cells and antigen spreading, supporting the observed clinical responses.

• A prospective phase I trial in metastatic pancreatic cancer will combine ELI-002 with RAS inhibitors (pan-RAS and allele-specific) and checkpoint inhibitors, with initiation planned for Q4 and readouts expected in Q1–Q2.